Treatment of Egyptian Hepatitis C Genotype 4 Infected Children (and Adolescents) With Combined Sofosbuvir & Daclatasvir
The Safety and Efficacy of Sofosbuvir & Daclatasvir Combined Therapy for Treatment of Egyptian Children and Adolescents With Chronic Hepatitis C (HCV)-Genotype 4
Sponsor: Egyptian Cure Bank
This PHASE3 trial investigates Hepatitis C Genotype 4 and is currently completed. Egyptian Cure Bank leads this study, which shows 8 recorded versions since 2017 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jul 2018 — Feb 2020 [monthly]
Completed PHASE3
Status: Enrolling By Invitation → Completed
-
Jun 2018 — Jul 2018 [monthly]
Enrolling By Invitation PHASE3
-
Apr 2017 — Jun 2018 [monthly]
Enrolling By Invitation PHASE3
First recorded
Mar 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Egyptian Cure Bank
- Society of Friends of Liver Patients in the Arab World (SLPAW)
- Yassin Abdelghaffar Charity Center for Liver Disease and Research
For direct contact, visit the study record on ClinicalTrials.gov .